WO2009104167A1 - A substance or composition for the treatment of cancer - Google Patents
A substance or composition for the treatment of cancer Download PDFInfo
- Publication number
- WO2009104167A1 WO2009104167A1 PCT/IB2009/050712 IB2009050712W WO2009104167A1 WO 2009104167 A1 WO2009104167 A1 WO 2009104167A1 IB 2009050712 W IB2009050712 W IB 2009050712W WO 2009104167 A1 WO2009104167 A1 WO 2009104167A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- dppe
- cancer
- pyridyl
- phase
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 34
- 201000011510 cancer Diseases 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims description 10
- 239000000126 substance Substances 0.000 title claims description 9
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims abstract description 26
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 14
- -1 hexafluorophosphate Chemical group 0.000 claims abstract description 12
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 9
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 9
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 7
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 150000002367 halogens Chemical group 0.000 claims abstract description 5
- 125000002577 pseudohalo group Chemical group 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 15
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 229910017673 NH4PF6 Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 136
- 239000010931 gold Substances 0.000 description 64
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 60
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 41
- 241000699670 Mus sp. Species 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 230000006907 apoptotic process Effects 0.000 description 21
- 230000022131 cell cycle Effects 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 230000018199 S phase Effects 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 230000004668 G2/M phase Effects 0.000 description 10
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 8
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 230000010337 G2 phase Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000006369 cell cycle progression Effects 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 6
- 229940127093 camptothecin Drugs 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical group [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 0 C*N(CCC1(C)C(C)C1C)*C Chemical compound C*N(CCC1(C)C(C)C1C)*C 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 238000004679 31P NMR spectroscopy Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- ISLJZDYAPAUORR-UHFFFAOYSA-N ethyl n-[2-[(5-nitrothiophene-2-carbonyl)amino]thiophene-3-carbonyl]carbamate Chemical compound C1=CSC(NC(=O)C=2SC(=CC=2)[N+]([O-])=O)=C1C(=O)NC(=O)OCC ISLJZDYAPAUORR-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 150000002940 palladium Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 231100000272 reduced body weight Toxicity 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical class SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- OLERZURONBJUJK-UHFFFAOYSA-N 2,6-dimethyl-4-nitropyridine Chemical compound CC1=CC([N+]([O-])=O)=CC(C)=N1 OLERZURONBJUJK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FAFGMAGIYHHRKN-UHFFFAOYSA-N 2-diphenylphosphanylethyl(diphenyl)phosphane;palladium Chemical compound [Pd].C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 FAFGMAGIYHHRKN-UHFFFAOYSA-N 0.000 description 1
- GBLNXAZZONXIQE-UHFFFAOYSA-N 2-dipyridin-2-ylphosphanylethyl(dipyridin-2-yl)phosphane Chemical compound C=1C=CC=NC=1P(C=1N=CC=CC=1)CCP(C=1N=CC=CC=1)C1=CC=CC=N1 GBLNXAZZONXIQE-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108050005848 Annexin A10 Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000004639 Schlenk technique Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- NCKJIJSEWKIXAT-DQRAZIAOSA-N [(z)-2-diphenylphosphanylethenyl]-diphenylphosphane Chemical group C=1C=CC=CC=1P(C=1C=CC=CC=1)/C=C\P(C=1C=CC=CC=1)C1=CC=CC=C1 NCKJIJSEWKIXAT-DQRAZIAOSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical group [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000003003 phosphines Chemical group 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000847 severe hepatotoxicity Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/006—Palladium compounds
- C07F15/0066—Palladium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Definitions
- THIS INVENTION relates to the treatment of cancer.
- the invention relates to a phosphine complex, to a substance or composition for use in the treatment of cancer, to a pharmaceutical composition, to the use of a phosphine complex in the manufacture of a medicament for use in the treatment of cancer, to a process for the preparation of a phosphine complex, and to a method of treating cancer.
- Cancer is not a single disease but a broad group of cell mutations characterised by malignant cells that are clearly distinguished from normal cells by uncontrolled growth.
- Cell mutations are caused by abnormalities in the sequence and expression of critical genes, most notably oncogenes and tumour suppressor genes.
- the language of cancer is to be found in the resulting deregulation of crucial biochemical pathways that control proliferation, the cell cycle, survival/apoptosis, angiogenesis, invasion and metastasis.
- Aberrant cellular growth is a primary cause in the development of malignant tumours, but additional events take place, which enable tumour cells to invade tissue barriers and metastasise to distant sites. These events include detachment of cells from the primary tumour, the crossing of tissue boundaries, entrance and exit from the circulatory system, the infiltration of distant organs, and the formation of metastatic implants.
- Herceptin (trade name), for the treatment of breast cancer) and the tumour vasculature
- DNA-interactive drugs in clinical use represent one of the most important drug classes in cancer therapy. There are three major types of these clinically important drugs: ⁇ The intercalators, which insert between the base pairs of the double helix and determine a significant change of DNA conformation being accompanied by unwinding and elongation of the duplex.
- the alkylators which react covalently with DNA bases.
- the DNA strand breakers which generate reactive radicals that produce cleavage of the polynucleotide strands.
- cytotoxic agents that exert their effects on all proliferating cells, both normal and cancerous. Since cytotoxic agents have a selectively 'antiproliferative' action rather than selective 'anti-cancer' properties, the therapeutic window for tumour vs. normal tissue is modest at best and toxic side effects are the norm. Most tumour types are resistant to current chemotherapy or become resistant during treatment. There is thus a need for new anticancer drugs. However, the clinical application of new anti-tumour drugs has been hindered by their low therapeutic index and lack of efficacy in humans. Thus, an approach to improve old and new anti-cancer drugs has been to manipulate their pharmacokinetic properties. Four interrelated factors determine pharmacokinetic behaviour of a drug: absorption, distribution, metabolism and excretion.
- Metal ions and metal coordination compounds are known to affect cellular processes in a dramatic way. This metal effect influences not only natural processes, such as cell division and gene expression, but also non-natural processes, such as toxicity, carcinogenicity, and anti-tumour chemistry. However, the mechanisms of action of metal-based drugs are often not well understood.
- Pd(II) salts form very stable complexes with tertiary phosphines and arsines. Based on the structural analogy between Pt(II) and Pd(II) complexes, some studies on Pd(II) compounds as suitable drugs have been carried out. However, advances in this area have been scarce probably due to kinetic reasons; it is well known that comparable Pt(II) compounds always react more slowly by a factor of 10 5 than corresponding Pd(II) complexes.
- Pd(II) and Pd(IV) complexes have been investigated for their cytotoxic anti-tumour activity.
- amine neutral ligands such as ethylenediamine, diaminocyclohexane, ammonia, pyridine and pyrimidine derivatives, alkylaminophosphine oxides, mercapto-imidazoles and pyrimidines.
- Promising anti-proliferative activity was found in Pd complexes with chelating ligands or alkyl- or aryl-thiosemicarbazones.
- dmnp 2,6-dimethyl-4-nitropyridine
- M is Pt or Pd;
- X is hexafluorophosphate, halogen or pseudo-halogen.
- a substance or composition for use in the treatment of cancer including a phosphine complex of the general formula (I) as hereinbefore described.
- a pharmaceutical composition which includes a phosphine complex of the general formula (I) as hereinbefore described, or a pharmaceutically acceptable salt thereof.
- the invention extends to a method of treating cancer, which includes administering to a patient a therapeutically effective amount of a phosphine complex of the general formula (I) as hereinbefore described, or a pharmaceutically acceptable salt thereof.
- the phosphine complex may be selected from the group consisting of
- the phosphine complex is selected from the group consisting of
- the phosphine complex is selected from the group consisting of
- M is Pt or Pd;
- X is hexafluorophosphate, halogen or pseudo-halogen, the process including
- the process may include reacting the intermediate compound of formula (I) with a hexafluorophosphate salt to produce the compound of formula (I) in which X " is PF 6 " .
- M 1 is Na
- M 2 is Pd
- Hal is Cl so that IvT 2 M 2 HaI 4 is Na 2 PdCI 4 .
- R 1 and R 2 are both 2-pyridyl.
- the process includes reacting M 1 2 M 2 HaI 4 in which M 2 is Pd with
- the hexafluorophosphate salt may be NH 4 PF 6 .
- Figure 1 shows a synthetic route in accordance with the invention for the preparation of bis(1 ,2-bis(di-2-pyhdyl)phosphino)ethane-P,P')-palladium(ll)
- Figure 2 shows an Ortep representation of bis(1 ,2-bis(di-2- pyridyl)phosphino)ethane-P,P')-palladium(ll) (hexafluorophosphate), i.e. Pg 8, with PF 6 " ions omitted for clarity.
- Figure 3 shows graphs of percentage of cells undergoing apoptosis and necrosis after treatment with compounds of the invention and reference gold compounds for 18 (a), 24 (b) and 48 hours (c), and also for cells incubated with camptothecin for 6 hours (d).
- the data is presented as a mean of three experiments.
- Figure 4 shows contour diagrams of FITC-Annexin V/PI flow cytometry of Jurkat cells cultured for 48 hours with Pg 8 of the invention, a gold reference compound and camptothecin.
- Diagram (a) is untreated, diagram (b) is Pg 8 (0.71 1 ⁇ M), diagram (c) is Pg 8 (1 .422 ⁇ M), diagram (d) is [Au(dppe)2]CI (0.131 ⁇ M), diagram (e) is [Au(dppe)2]CI (0.262 ⁇ M) and diagram (f) is camptothecin (1 ⁇ M).
- Figure 5 shows representative histograms and graphs showing changes in the cell cycle profiles (G 0 /Gi , S and G 2 /M phases) after 18, 24 and 48 hours for untreated Jurkat cells.
- Figure 6 shows representative histograms and graphs showing changes in the cell cycle profiles (G 0 /Gi, S and G 2 /M phases) after 18, 24 and 48 hours for 0.71 1 ⁇ M of Pg 8 on cell cycle of Jurkat cells.
- Figure 7 shows representative histograms and graphs showing changes in the cell cycle profiles (G 0 /Gi, S and G 2 /M phases) after 18, 24 and 48 hours for 1 .422 ⁇ M of Pg 8 on cell cycle of Jurkat cells.
- Figure 8 shows representative histograms and graphs showing changes in the cell cycle profiles (G 0 /Gi, S and G 2 /M phases) after 18, 24 and 48 hours for 0.131 ⁇ M of [Au(dppe) 2 ]CI on cell cycle of Jurkat cells.
- Figure 9 shows representative histograms and graphs showing changes in the cell cycle profiles (G 0 /Gi, S and G 2 /M phases) after 18, 24 and 48 hours for 0.262 ⁇ M of [Au(dppe) 2 ]CI on cell cycle in Jurkat cells.
- Figure 10 shows a comparison of cell cycle progression of untreated Jurkat cells and those treated with Pg 8 (0.71 1 and 1.422 M) and [Au(dppe) 2 ]CI (0.131 and 0.262 ⁇ M) after 18, 24 and 48 h. Differences in G 0 /Gi , S and G 2 /M phases of untreated and treated cells were compared by 2-way ANOVA. Significance was established at P ⁇ 0.05.
- Figure 1 1 shows graphs of mean body weight changes of control and treated mice in phase 1 of Study 4.
- Figure 12 shows graphs of mean body weight changes of control and treated mice in phase 2 of Study 4.
- Figure 13 shows a graph of AST levels of untreated mice and mice treated with [Au(dppe) 2 ]CI (3 ⁇ mol/kg) and Pg 8 (3 and 6 ⁇ mol/kg) in Phase 1 of Study 4.
- Figure 14 shows a graph of AST levels of untreated mice and mice treated with
- Figure 15 shows GGT levels of untreated mice and mice treated with [Au(dppe) 2 ]CI (3 ⁇ mol/kg) and Pg 8 (3 and 6 ⁇ mol/kg) in Phase 1 of Study 4.
- Figure 16 shows GGT levels of untreated mice and mice treated with [Au(dppe) 2 ]CI (6 ⁇ mol/kg) and Pg 8 (12 and 15 ⁇ mol/kg) in Phase 2 of Study 4.
- Figure 17 shows Creatinine levels of untreated mice and mice treated with [Au(dppe) 2 ]CI (3 ⁇ mol/kg) and Pg 8 (3 and 6 ⁇ mol/kg) in Phase 1 of Study 4.
- Figure 18 shows Creatinine levels of untreated mice and mice treated with [Au(dppe) 2 ]CI (6 ⁇ mol/kg) and Pg 8 (12 and 15 ⁇ mol/kg) in Phase 1 of Study 4.
- Figure 19 shows comparison of distribution of [ 198 Au(dppe) 2 ]CI (5 and 10 ⁇ M) and [ 103 Pd(d2pyrpe) 2 ][PF 6 ] 2 (5 and 10 ⁇ M) in Jurkat cells after exposure for 1 h. The results shown here were obtained from an average of 8 different cell populations and the values are means ⁇ SEM.
- Figure 20 shows the biodistribution of selected organs of adult male Sprague Dawley rats as expressed as a percentage of injected dose per gram of [ 198 Au(dppe) 2 ]CI and [ 103 Pd(d2pyrpe) 2 ][PF 6 ] 2 .at 6 h. Illustrated values are means ⁇ S.E.M.
- Elemental analysis (empirical formulae shown) was determined by the Institute for Soil, climate and Water, Pretoria. Fast atomic bombardment mass spectra were recorded with a VG70SEQ by micromass at the University of the Witwatersrand. Melting points were recorded in unsealed capillaries and are uncorrected.
- Pg 8 was prepared according to the synthetic route shown in Figure 1. The first step was carried out under an argon atmosphere, using standard Schlenk techniques as the ligand is known to decompose slowly in the presence of oxygen. Pg 8 was prepared from the intermediate (bis(1 ,2-bis(di-2-pyhdylphosphino)ethane palladium) dichloride, [Pd(d2pyrpe) 2 ].2CI.
- 1a signifies peaks for the mono-chelated compound while b shows those peaks that belong to the bischelated compound.
- Pg 8 crystallises in the non-centrosymetric space group Pnna with half a molecule of the palladium complex and two ions of PF 6 in the asymmetric unit.
- the two PF 6 ions are disordered.
- One has only the equilateral fluoride atoms disordered in a general position while the second has both axial and equilateral fluoride atoms disordered also in a general position but resulting in distorted octahedral geometry.
- Connection of molecules in the crystal is mainly through C-H... F intermolecular interactions.
- Packing in the crystal is such that the solvate molecules are sitting in the voids between the palladium complex molecules with the less disordered ions of PF 6 being on the same axis as Pd atoms while the more disordered PF 6 ion is positioned between the Pd complexes.
- the conformations of the ligands are such that the pyridyl rings get positioned more above and below the coordination plane. Two pyridyl nitrogens, one on each side of the coordination plane are just over 3A from the Pd.
- Table 1 Crystal Data for [Pd(d2pyrpe) 2 ][PF 6 ] 2
- Supplemented cell culture medium Cell culture medium with 10% foetal calf serum (FCS).
- FCS foetal calf serum
- PBS Phosphate buffered saline
- PHA Phytohaemagglutinin
- Test compounds (6 and [Au(dppe) 2 ]CI) - dissolved in DMSO (20 mM) and diluted in cell culture medium.
- DMSO DMSO
- FCS heat- inactivated serum
- EACC ovarian cancer-cisplatin resistant
- RPMI ⁇ MCF-7- human breast cancer
- DMEM DMEM
- RPMI ⁇ DU 145- human prostate cancer
- Human lymphocytes (resting and PHA stimulated)- fresh venous blood was obtained from healthy volunteers followed by isolation of lymphocytes.
- Chicken embryo fibroblasts- cells were isolated from chicken embryos.
- MTT is a pale yellow substance that is metabolised to dark blue formazan crystals by metabolically active cells. The amount of formazan produced is directly proportional to the amount of cells over a wide range.
- 80 ⁇ l of medium (60 ⁇ l in the case of the lymphocytes earmarked to be stimulated) was dispensed into each well of a 96 well tissue culture plate (micro-titer plate).
- 100 ⁇ l of cell suspension (2 x 10 4 - 2 x 10 6 cells/ml/well depending on the cell type) was added and then allowed to incubate for 1 hour at 37 Q C in an atmosphere of 5% CO 2
- 20 ⁇ l of the experimental drug (eight varying concentrations) was added in triplicate to the wells.
- control wells received 20 ⁇ l of growth medium instead of the experimental drug.
- Lymphocytes earmarked to be stimulated received 20 ⁇ l PHA 5 minutes after the addition of the drug.
- the cells were washed with 150 ⁇ l PBS (per well) and centrifuged for 10 min at 2000 rpm (800 g) (Beckman TJ 6 centrifuge). The supernatant was removed and plates were left to dry in the dark. 100 ⁇ l DMSO was added to each well to solubilise the formazan crystals and the plates were shaken for 2-4 hours. Culture plates were read on a plate reader using a wavelength of 570 nm and a reference wavelength of 630 nm.
- IC 5 O the concentration ( ⁇ M) of the experimental compound inducing a 50% decrease in cell growth).
- IC 5 O value calculations were performed with the GraphpadTM program and are tabulated below in Table 2.
- Table 2 IC 50 values ( ⁇ M) and S. E. M ( ⁇ ) of 7 compounds on various cancer cell lines as well as normal cells. The values are presented as a mean of three experiments carried out in triplicate.
- Pg 1 the least toxic compound followed by Pg 6 and Pg 5 ⁇ Table 2).
- Pg 8 was the most toxic of the palladium complexes followed by Pg 4a and Pg 3.
- prostate cancer (DU-145) was the most sensitive cell line (IC 5 O values of 0.253-9.380 ⁇ M) while ovarian cancer-cisplatin resistant cell line (A2780-cis) was the most resistant (IC 5 O values of 2.029-> 50 ⁇ M).
- Human ovarian cancer cell line- cisplatin sensitive (A2780) was sensitive to all the palladium complexes with IC 50 values of 0.617 ⁇ M (Pg 3), 0.136 ⁇ M (Pg 4a) and 0.974 ⁇ M (Pg 8). Overall, Pg 8 was the most toxic (over the whole range of cells) of the novel compounds followed by Pg 4a which showed comparative activity against Jurkat and MCF-7 cell lines.
- Pg 8 was selected for further tests in an effort to elucidate its mechanism of action. It was selected due the fact that it showed greater toxicity to a wider range of cancer lines than the rest of the invention compounds.
- [Au(dppe) 2 ]CI was included in these investigations as a standard. Jurkat cells were used for the remainder of the assays as they could be compared to lymphocytes.
- the aim of this assay was to evaluate the induction of apoptosis and/or necrosis by [Au(dppe) 2 ]CI and Pg 8 on Jurkat cells with the Annexin V binding assay. Untreated and treated cells were evaluated for apoptosis by flow cytometry. Camptothecin (1 ⁇ M), a topoisomerase I inhibitor that efficiently induces apoptosis in Jurkat cells was used as a positive control.
- PBS Phosphate buffered saline
- Binding buffer (238 mg Hepes, 876 mg NaCI, 37.3 mg KCI, 26.5 mg CaCI 2 , 9.5 mg MgCI 2 in de-ionised water, at pH 7.4) ⁇ Annexin V- FITC ( BD Biosciences Pharmingen)
- the human Jurkat cell line was cultured in RPMI 1640 supplemented with 10% v/v heat-inactivated FCS and 1 % penicillin-streptomycin. Cells were maintained in a humidified atmosphere of 5% carbon dioxide at 37 °C.
- Cells (1 x 10 5 cells/ml) were treated with [Au(dppe) 2 ]CI and Pg 8 for 18, 24 and 48 h in cell culture flasks. After the incubation period, cells were decanted from flasks and centrifuged for 5 min at 200 g. The cell pellet was washed with PBS (1 % FCS) and resuspended in 1 ml binding buffer. 100 ⁇ l of cell suspension was transferred to flow cytometer tubes. 5 ⁇ l of Annexin V-FITC and 10 ⁇ l propidium iodide were added to some tubes (unstained samples were also prepared). The cell suspensions were mixed gently and incubated for 15 min in the dark at room temperature (25 °C). 400 ⁇ l of binding buffer was then added to each tube and analysis was carried out within an hour with a flow cytometer (Beckman Coulter FC 500). Statistical methods
- Figure 3 shows graphs indicating the percentages of cells undergoing various stages of apoptosis.
- Figure 4 shows actual histograms of treated and untreated cells undergoing apoptosis (48 h). After incubation of Jurkat cells with the compounds for 18 and 24 h, no significant differences were noted between the untreated and the treated groups as between 85 and 90% of cells were viable. However, after exposure of the cells for 48 h, significant differences were observed. Untreated cells had an average of 85% of cells in a viable state and only 8% at the early apoptotic stage.
- Pg 8 (0.71 1 and 1 .422 ⁇ M) significantly induced apoptosis in 25% of the cells while 14% of cells had undergone necrosis. Only 50% of the cells were viable in this group.
- camptothecin (1 ⁇ M) induced apoptosis in Jurkat cells within a short time. After incubation for 6h, about 40% of the cells were in the late apoptotic stage. Viable cells were just over 50% while only 2% of the cells were necrotic.
- DNA topoisomerase I and Il inhibitors induce apoptosis in various cell lines and this is due to DNA-protein complex formation stabilised by DNA topoisomerase I inhibitors that ultimately signal the onset of apoptosis.
- Study 2 has shown that Pg 8 and [Au(dppe) 2 ]CI caused Jurkat cells to undergo apoptosis after exposure for 48 h.
- the aim of this study was to determine if cell death was as a result of cell cycle arrest by these compounds.
- Cell cycle analysis was performed using flow cytometric evaluation of DNA content.
- PBS Phosphate buffered saline
- the human Jurkat cell line was cultured in RPMI 1640 supplemented with 10% v/v heat-inactivated FCS and 1 % penicillin-streptomycin. Cells were incubated with the experimental compounds for 18, 24 and 48 hours at 37 °C and 5% carbon dioxide.
- Cells (1 x 10 5 cells/ml) were treated with [Au(dppe) 2 ]CI and Pg 8 for 18, 24 and 48h in cell culture flasks. After the incubation period, they were decanted from flasks and centrifuged for 5 min at 200 g. The cell pellet was re-suspended in 500 ⁇ l PBS and chilled on ice. The cold cell suspension was then added rapidly to flow cytometer tubes containing 500 ⁇ l of ice cold ethanol. Mixing was carried out by forcing air bubbles through the suspension and then kept on ice for 15 minutes.
- RNAse 2mg/ml 1 .12% w/v sodium citrate
- Pl 125 ⁇ l of Pl was added to each tube and mixed well. Samples were allowed to stand for 30 minutes at room temperature before analysis by flow cytometry (Beckman Coulter FC 500). DNA histograms were collected and estimation of the percentages of cells in Gi , S and G 2 /M was performed with a computer software program (Multicycle, Phoenix Flow systems, San Diego, CA).
- the DNA histogram yields the relative number of cells in G 1 ZG 0 , S, and G 2 /M phases of the cell cycle. Although some information about cell cycle progression can be deduced by following changes in the cell cycle phases with time, it gives static information. For example, although it is possible to estimate the percentage of cells in S phase, the measurement does not directly tell whether those cells are still moving through the S phase. A very distinct connection has been forged between the cell cycle clock apparatus and apoptosis. The paclitaxel-induced apoptosis of human breast cancer cells has been found to depend upon the induction of the cdc2 kinase at the G 2 /M phase transition of the cell cycle.
- Inbred female Balb/C mice of 6-8 weeks were used and housed in standard mouse cages in rooms with controlled environmental conditions. The animals were fed normal pellets (EPOL (trade name)) and water ad libitum.
- mice The study was carried out in two phases with 4 groups of 6 mice each being used per phase (total of 48 mice).
- the MTD of [Au(dppe) 2 ]CI was previously shown to be 3.0 ⁇ mol/kg/day for 5 days and hence this concentration was used as a guideline.
- the weight of the mice was determined to adapt the dosages according to their body weight.
- the experimental compound Pg 8 and [Au(dppe) 2 ]CI (standard) were dissolved in analytical quality ethanol, with subsequent addition of water to make up a final dose volume of 0.5 ml and a concentration of 5% ethanol.
- the dosages were prepared immediately prior to each ip. administration.
- mice were injected ip. each day for 5 days.
- phase 1 the ethanol-water solution and the first and second dosages of 3 ⁇ mol/kg and 6 ⁇ mol/kg were administered each day from day 1 to 5.
- Phase 2 followed whereby the ethanol-water solution and the third and fourth dosages of 12 ⁇ mol/kg and 15 ⁇ mol/kg were administered each day from day 1 to 5.
- the mice were weighed followed by anaesthetisation via isoflurane inhalation. While they were at the surgical plane of anaesthesia, maximum blood was drawn via cardiac puncture. The animals were then further exposed to isoflurane until death occurred.
- Mice in phase 2 were dissected and major organs (liver, heart and kidneys) were weighed.
- Body weights were recorded immediately prior to dosing (on day 1 ) so that an objective monitoring of weight could be done, indicating food intake, which is a good measure for animal well-being.
- the animals were also monitored for pain and stress (behavioural changes) immediately after the injection.
- GGT levels shown in Figure 15 were also slightly elevated (P ⁇ 0.05) in the group treated with [Au(dppe) 2 ]CI (3 ⁇ mol/kg) when compared to the untreated mice. However, the levels did not differ significantly with the mice treated with Pg 8 (12 and 15 ⁇ mol/kg). In Phase 2 of the study, GGT levels did not show significant differences in all the groups (untreated and treated). Notably, the mice treated with 12 ⁇ mol/kg of Pg 8 exhibited higher levels of GGT than the highest dose (15 ⁇ mol/kg) ( Figure 16). However, this difference was not significant.
- Creatinine levels ( Figure 17 and 18) in all the groups did not vary significantly. This is an indication of lack of toxicity to the kidneys.
- [Au(dppe) 2 ]CI showed greater in vitro activity against cancer cells than Pg 8. It was also very toxic to the normal cells such as lymphocytes, chicken embryo fibroblasts and hepatocytes. This lack of selectivity is exhibited in vivo as the acute exposure to mice caused reduced body weight. Measurement of biochemical parameters revealed that AST levels were greatly elevated which may imply damage to organs. As an intracellular enzyme, AST is released into the blood in proportion to the number of damaged cells. While the former drug may show potency against cancer cell lines, its lack of selectivity is dose-limiting. As mentioned earlier, it was also active in tumour implanted mice.
- Pg 8 was more tolerable although the group treated with the highest dose (15 ⁇ mol/kg) showed slightly reduced weight gain as compared to the rest (3, 6 and 12 ⁇ mol/kg).
- the desired outcome is that the compound shows in vivo anti-tumour activity especially in distal tumours. This would be determined by good bio-availability which is influenced by factors such as stability against metabolic, pathways, adsorption, plasma level concentrations and excretion rates. Study 5
- PBS Phosphate buffered saline
- Human T-cell lines (Jurkat) were cultured in RPMI 1640 supplemented with 10% v/v heat-inactivated FCS and 1 % penicillin-streptomycin. The cell culture was maintained at 37 0 C and 5% CO 2 .
- the animals were anaesthetised by an intraperitoneal (ip.) injection of a 6 % sodium pentobarbitone solution at a dose of 1 ml/kg.
- ip. intraperitoneal
- a 24 G jelco was inserted into the tail vein of the animals to administer the radio- labelled compounds.
- Two animals per group were scanned in parallel with an Elscint Gamma Camera at the Diagnostic Imaging unit at Onderstepoort in order to obtain the radionuclide imaging.
- Two minute static studies were performed every half an hour up to 6 hours, lsoflurane was used to immobilize the animals for the 2 minute static studies.
- the animals were sacrificed using an lsoflurane overdose after a 6 hour period.
- the organs were separated and counted in a well type counter at NECSA. From the organ counts as well as the reference activity in a syringe the %ID/g (Injected Dose/gram) was calculated.
- the biodistribution ( Figure 20) showed predominantly high reticulo- endothelial uptake for all compounds.
- the largest concentration of [Au(dppe) 2 ]CI was found in the lungs followed by the spleen.
- the highest concentration of Pg 8 was found in the spleen followed by the liver.
- Hydrophilic drugs are expected to have a limited biodistribution compared to lipophilic drugs. This might imply a more selective tumour uptake.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a phosphine complex of the general formula (I) in which M is Pt or Pd; R 1 and R 2 are independently Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl; the two Y substituents are independently CH 2 CH 2 or CH=CH; and X is hexafluorophosphate, halogen or pseudo-halogen. The phosphine complex is useful in the treatment of cancer.
Description
A SUBSTANCE OR COMPOSITION FOR THE TREATMENT OF CANCER
THIS INVENTION relates to the treatment of cancer. In particular, the invention relates to a phosphine complex, to a substance or composition for use in the treatment of cancer, to a pharmaceutical composition, to the use of a phosphine complex in the manufacture of a medicament for use in the treatment of cancer, to a process for the preparation of a phosphine complex, and to a method of treating cancer.
Cancer is not a single disease but a broad group of cell mutations characterised by malignant cells that are clearly distinguished from normal cells by uncontrolled growth. Cell mutations are caused by abnormalities in the sequence and expression of critical genes, most notably oncogenes and tumour suppressor genes. The language of cancer is to be found in the resulting deregulation of crucial biochemical pathways that control proliferation, the cell cycle, survival/apoptosis, angiogenesis, invasion and metastasis. Aberrant cellular growth is a primary cause in the development of malignant tumours, but additional events take place, which enable tumour cells to invade tissue barriers and metastasise to distant sites. These events include detachment of cells from the primary tumour, the crossing of tissue boundaries, entrance and exit from the circulatory system, the infiltration of distant organs, and the formation of metastatic implants.
The treatment of cancer has traditionally used agents that interfere with the cell division process. More recently, research and novel therapies have targeted the growth signals that drive the proliferation and survival of cancer cells (for example,
Herceptin (trade name), for the treatment of breast cancer) and the tumour vasculature
(for example, anti-bodies against vascular endothelial growth factor).
DNA-interactive drugs in clinical use represent one of the most important drug classes in cancer therapy. There are three major types of these clinically important drugs:
■ The intercalators, which insert between the base pairs of the double helix and determine a significant change of DNA conformation being accompanied by unwinding and elongation of the duplex.
■ The alkylators, which react covalently with DNA bases. ■ The DNA strand breakers, which generate reactive radicals that produce cleavage of the polynucleotide strands.
Increased cure rates have been achieved in childhood cancer, testicular cancer, leukaemia and lymphoma and survival improvements have been obtained with adjuvant drug treatment of breast and ovarian cancer. However, the goal of routine care or long term management of cancer as a chronic disease remains frustratingly elusive and the development of preventative agents is even more embryonic and challenging.
The majority of current anti-cancer drugs are cytotoxic agents that exert their effects on all proliferating cells, both normal and cancerous. Since cytotoxic agents have a selectively 'antiproliferative' action rather than selective 'anti-cancer' properties, the therapeutic window for tumour vs. normal tissue is modest at best and toxic side effects are the norm. Most tumour types are resistant to current chemotherapy or become resistant during treatment. There is thus a need for new anticancer drugs. However, the clinical application of new anti-tumour drugs has been hindered by their low therapeutic index and lack of efficacy in humans. Thus, an approach to improve old and new anti-cancer drugs has been to manipulate their pharmacokinetic properties. Four interrelated factors determine pharmacokinetic behaviour of a drug: absorption, distribution, metabolism and excretion.
Metal ions and metal coordination compounds are known to affect cellular processes in a dramatic way. This metal effect influences not only natural processes, such as cell division and gene expression, but also non-natural processes, such as toxicity, carcinogenicity, and anti-tumour chemistry. However, the mechanisms of action of metal-based drugs are often not well understood.
The interactions of heavy metals such as platinum (Pt) and gold (Au) with N, S donor atoms have been recognised for their anti-cancer properties with the
potential to develop metal-based drugs. The successful use of metal complexes as therapeutic and diagnostic agents depends on the control of their kinetic and thermodynamic properties through appropriate choice of oxidation state, types and numbers of bound ligands, and coordination geometry.
Pd(II) salts form very stable complexes with tertiary phosphines and arsines. Based on the structural analogy between Pt(II) and Pd(II) complexes, some studies on Pd(II) compounds as suitable drugs have been carried out. However, advances in this area have been scarce probably due to kinetic reasons; it is well known that comparable Pt(II) compounds always react more slowly by a factor of 105 than corresponding Pd(II) complexes.
Relatively few Pd(II) and Pd(IV) complexes have been investigated for their cytotoxic anti-tumour activity. Among them were complexes with amine neutral ligands such as ethylenediamine, diaminocyclohexane, ammonia, pyridine and pyrimidine derivatives, alkylaminophosphine oxides, mercapto-imidazoles and pyrimidines. Promising anti-proliferative activity was found in Pd complexes with chelating ligands or alkyl- or aryl-thiosemicarbazones. Two kinds of Pd complexes with 2,6-dimethyl-4-nitropyridine (dmnp) were prepared and tested for cytotoxicity in vitro against 4 human cancer cells: SW707 (adenocarcinoma of the rectum), T47D (breast cancer), HCV (bladder cancer) and A549 (non-small cell lung carcinoma). Free ligand and [Pd2(dmnp)2CI4] showed moderate activity while the [Pd(dmnp)2CI2] was strongly active against all 4 cell lines. The greatest activity was observed against T47D, which is the line known as poor responsive (resistant) on platinum-based drugs. The ID50 (concentration of the compound required to kill 50% of tumour cells) values for the most potent compound ranged from 0.46-8.4 μg/ml.
The bis-chelated 1 :2; Au(l):diphosphine complex, [Au(dppe)2]CI (dppe = Ph2PCH2CH2PPh2) shown below has been investigated as a cancer drug.
[Au{dppe)?]CI
This complex exhibits anti-tumour activity against a range of tumour models in mice and structure activity relationships have been evaluated for a wide range of diphosphine ligands and their metal complexes. Preclinical development of [Au(dppe)2]+ was abandoned after the identification of severe hepatotoxicity in dogs attributed to alterations in mitochondrial function. [Au(dppe)2]+ is extremely lipophilic (containing 8 hydrophobic phenyl substituents) and consequently non-selectively targets mitochondria in all cells.
Pd analogues of [Au(dppe)2]CI have previously being prepared and tested for anti-tumour activity. These complexes, [Pd(dppe)2]CI2 and [Pd(dppen)2]CI2 (dppen = 1 ,2-bis(diphenylphosphino)ethylene), were tested for cytotoxicity against murine and human tumour cell lines. The results showed low potency. They were also tested for anti-tumour activity on intraperitoneal (ip.)-implanted tumours and both of them showed inactivity and were not well tolerated.
According to one aspect of the invention, there is provided a phosphine complex of the general formula (I)
in which
M is Pt or Pd; R1 and R2 are independently Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl;
the two Y substituents are independently CH2CH2 or CH=CH; and X is hexafluorophosphate, halogen or pseudo-halogen.
According to another aspect of the invention, there is provided a substance or composition for use in the treatment of cancer, the substance or composition including a phosphine complex of the general formula (I) as hereinbefore described.
According to a further aspect of the invention, there is provided a pharmaceutical composition which includes a phosphine complex of the general formula (I) as hereinbefore described, or a pharmaceutically acceptable salt thereof.
According to yet another aspect of the invention there is provided the use of a phosphine complex of the general formula (I) as hereinbefore described in the manufacture of a medicament for use in the treatment of cancer.
The invention extends to a method of treating cancer, which includes administering to a patient a therapeutically effective amount of a phosphine complex of the general formula (I) as hereinbefore described, or a pharmaceutically acceptable salt thereof.
The phosphine complex may be selected from the group consisting of
In one embodiment of the invention, the phosphine complex is selected from the group consisting of
In another embodiment of the invention the phosphine complex is selected from the group consisting of
In yet another embodiment of the invention, the phosphine complex is selected from the group consisting of
Preferably, the phosphine complex is
According to yet a further aspect of the invention, there is provided a process for the preparation of a phosphine complex of the general formula (I)
in which
M is Pt or Pd; R1 and R2 are independently Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl; the two Y constituents are independently CH2CH2 or CH=CH; and X is hexafluorophosphate, halogen or pseudo-halogen, the process including
reacting
R1 and R2 are independently Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl, and Y is CH2CH2 Or CH=CH, with M 1 2 M2 HaI4 in which M1 is an alkali metal, M2 is Pd or Pt and Hal is Cl or Br to produce an intermediate compound of formula (I) in which X" is Cl" or Br".
The process may include reacting the intermediate compound of formula (I) with a hexafluorophosphate salt to produce the compound of formula (I) in which X" is PF6 ".
In one embodiment of the invention, M1 is Na, M2 is Pd and Hal is Cl so that IvT2M2HaI4 is Na2PdCI4.
Preferably R1 and R2 are both 2-pyridyl.
Preferably, the process includes reacting M1 2 M2 HaI4 in which M2 is Pd with
in which Y is CH2CH2.
The hexafluorophosphate salt may be NH4PF6.
The invention will be further described in more detail by way of the following drawings, Example and Studies.
In the drawings:
Figure 1 shows a synthetic route in accordance with the invention for the preparation of bis(1 ,2-bis(di-2-pyhdyl)phosphino)ethane-P,P')-palladium(ll)
(hexafluorophosphate), i.e. [Pd(d2pyrpe)2][PF6]2 or Pg 8.
Figure 2 shows an Ortep representation of bis(1 ,2-bis(di-2- pyridyl)phosphino)ethane-P,P')-palladium(ll) (hexafluorophosphate), i.e. Pg 8, with PF6 " ions omitted for clarity.
Figure 3 shows graphs of percentage of cells undergoing apoptosis and necrosis after treatment with compounds of the invention and reference gold compounds for 18 (a), 24 (b) and 48 hours (c), and also for cells incubated with camptothecin for 6 hours (d). The data is presented as a mean of three experiments.
Figure 4 shows contour diagrams of FITC-Annexin V/PI flow cytometry of Jurkat cells cultured for 48 hours with Pg 8 of the invention, a gold reference compound and camptothecin. One representative experiment is shown. Diagram (a) is untreated, diagram (b) is Pg 8 (0.71 1 μM), diagram (c) is Pg 8 (1 .422 μM), diagram (d) is [Au(dppe)2]CI (0.131 μM), diagram (e) is [Au(dppe)2]CI (0.262 μM) and diagram (f) is camptothecin (1 μM).
Figure 5 shows representative histograms and graphs showing changes in the cell cycle profiles (G0/Gi , S and G2/M phases) after 18, 24 and 48 hours for untreated Jurkat cells.
Figure 6 shows representative histograms and graphs showing changes in the cell cycle profiles (G0/Gi, S and G2/M phases) after 18, 24 and 48 hours for 0.71 1 μM of Pg 8 on cell cycle of Jurkat cells.
Figure 7 shows representative histograms and graphs showing changes in the cell cycle profiles (G0/Gi, S and G2/M phases) after 18, 24 and 48 hours for 1 .422 μM of Pg 8 on cell cycle of Jurkat cells.
Figure 8 shows representative histograms and graphs showing changes in the cell cycle profiles (G0/Gi, S and G2/M phases) after 18, 24 and 48 hours for 0.131 μM of [Au(dppe)2]CI on cell cycle of Jurkat cells.
Figure 9 shows representative histograms and graphs showing changes in the cell cycle profiles (G0/Gi, S and G2/M phases) after 18, 24 and 48 hours for 0.262 μM of [Au(dppe)2]CI on cell cycle in Jurkat cells.
Figure 10 shows a comparison of cell cycle progression of untreated Jurkat cells and those treated with Pg 8 (0.71 1 and 1.422 M) and [Au(dppe)2]CI (0.131 and 0.262 μM) after 18, 24 and 48 h. Differences in G0/Gi , S and G2/M phases of untreated and treated cells were compared by 2-way ANOVA. Significance was established at P<0.05.
Figure 1 1 shows graphs of mean body weight changes of control and treated mice in phase 1 of Study 4.
Figure 12 shows graphs of mean body weight changes of control and treated mice in phase 2 of Study 4.
Figure 13 shows a graph of AST levels of untreated mice and mice treated with [Au(dppe)2]CI (3 μmol/kg) and Pg 8 (3 and 6 μmol/kg) in Phase 1 of Study 4.
Figure 14 shows a graph of AST levels of untreated mice and mice treated with
[Au(dppe)2]CI (6 μmol/kg) and Pg 8 (12 and 15 μmol/kg) in Phase 2 of Study 4.
Figure 15 shows GGT levels of untreated mice and mice treated with [Au(dppe)2]CI (3 μmol/kg) and Pg 8 (3 and 6 μmol/kg) in Phase 1 of Study 4.
Figure 16 shows GGT levels of untreated mice and mice treated with [Au(dppe)2]CI (6 μmol/kg) and Pg 8 (12 and 15 μmol/kg) in Phase 2 of Study 4.
Figure 17 shows Creatinine levels of untreated mice and mice treated with [Au(dppe)2]CI (3 μmol/kg) and Pg 8 (3 and 6 μmol/kg) in Phase 1 of Study 4.
Figure 18 shows Creatinine levels of untreated mice and mice treated with [Au(dppe)2]CI (6 μmol/kg) and Pg 8 (12 and 15 μmol/kg) in Phase 1 of Study 4.
Figure 19 shows comparison of distribution of [198Au(dppe)2]CI (5 and 10 μM) and [103Pd(d2pyrpe)2][PF6]2 (5 and 10 μM) in Jurkat cells after exposure for 1 h. The results shown here were obtained from an average of 8 different cell populations and the values are means ±SEM.
Figure 20 shows the biodistribution of selected organs of adult male Sprague Dawley rats as expressed as a percentage of injected dose per gram of [198Au(dppe)2]CI and [103Pd(d2pyrpe)2][PF6]2.at 6 h. Illustrated values are means ±S.E.M.
Example
Solvents were distilled from sodium/benzophenone ketyl or calcium hydride and degassed. NMR spectra were recorded in c/-dimethylsulphoxide at 298 K using the following Bruker instruments; AVANCE 300 and ARX 300 (1 H, 300.1 MHz; 13C, 75.5 MHz; 31 P, 121 .5 MHz) and referenced internally to residual solvent resonances (data in δ) in the case of 1H and 13C NMR spectra. The 31P spectra were referenced externally to 85% H3PO4. 13C and 31P NMR spectra were proton decoupled. First order analysis was used to assign the spectra. Elemental analysis (empirical formulae shown) was determined by the Institute for Soil, Climate and Water, Pretoria. Fast atomic bombardment mass spectra were recorded with a VG70SEQ by micromass at the University of the Witwatersrand. Melting points were recorded in unsealed capillaries and are uncorrected.
Pg 8 was prepared according to the synthetic route shown in Figure 1. The first step was carried out under an argon atmosphere, using standard Schlenk techniques as the ligand is known to decompose slowly in the presence of oxygen. Pg 8 was prepared from the intermediate (bis(1 ,2-bis(di-2-pyhdylphosphino)ethane
palladium) dichloride, [Pd(d2pyrpe)2].2CI. 1 ,2-bis(di-2-pyridylphosphino)ethane (540 mg, 1 .342 mmol) was added to a solution of disodium palladium tetrachloride, Na2PdCI4, (200 mg, 0.680 mmol) in tetrahydrofuran. The reddish-brown solution turned to deep yellow after 20 minutes of stirring. The resultant mixture was stirred for 12 hours at room temperature to yield a yellow precipitate. Filtration was carried out and the remaining solid was dried in vacuo. Yield (crude): 430 mg.
1H NMR (dimethylsulphoxide, 300 MHz): δ la2.93 [broad d (2JPH= 21 .35 Hz), bridging
CH2, 4H], b3.01 (broad s, bridging CH2, 8H), b7.53 (m, Ph, 16H), a7.61 (m, Ph, 4H), b7.93 (m, Ph, 8H), a7.99 (m, Ph,
4H), a8.1 1 (m, Ph, 4H), b8.33 (m, Ph, 8H), a8.76 (m, Ph, 4H)
In the aforegoing, 1a signifies peaks for the mono-chelated compound while b shows those peaks that belong to the bischelated compound.
31P NMR (dimethylsulphoxide, 121 .5 MHz): δ bischelate complex (64.0, s) and monochelated complex (70.4, s).
A solution of ammonium hexafluorophosphate, NH4PF6, (70 mg, 0.429 mmol) in acetone (5 ml) was added to a stirred solution of [Pd(d2pyrpe)2]CI2 (220 mg, -0.224 mmol) in acetone (40ml). On addition of ammonium salt, the cloudy mixture dissolved slightly and immediately turned from yellow to white. The mixture was stirred for 1 hour followed by filtration over celite 545. The colourless filtrate was reduced in vacuo to ~3ml and ether (20ml) was added to facilitate further precipitation. The pale yellow precipitate was washed with ether (3 x 5ml). It was then dried in vacuo. Yield: 100 mg (37 %)
1H NMR (dimethylsulphoxide, 300 MHz): δ 2.85 (broad s, bridging CH2, 8H), 7.46 (m, Ph, 8H), 7.67 (m, Ph, 8H), 7.74 (m, Ph, 8H), 8.42 (m, Ph,
8H). 31P NMR (dimethylsulphoxide, 121 .5 MHz): δ 64.0, s, -143 (spt, 1 JPF = 71 1 Hz, PF6 ").
13C NMR (dimethylsulphoxide, 75.5 MHz): δ 25.8 (s, bridging CH2, 4C), 126.5 (p-pyr,
8C), 132.1 (d, o-pyr, 8C), 137.2 (m-pyr, 8C), 151 .0 (CN, 8C). Ipso-C not observed.
Analysis calculated for C44H40N8P6Fi2Pd: C, 44.00; N, 9.33; H, 3.36. Analysis found: C, 44.26; N, 9.32; H, 3.31 %.
MS-FAB: 1054 M+- PF6; 910 M+-2PF6.
Colourless single crystals of Pg 8 were obtained from DMF solution by slow diffusion of ether. The molecular structure of the compound is illustrated in Figure 2 and crystal data is presented in Table 1 .
Pg 8 crystallises in the non-centrosymetric space group Pnna with half a molecule of the palladium complex and two ions of PF6 in the asymmetric unit. The two PF6 ions are disordered. One has only the equilateral fluoride atoms disordered in a general position while the second has both axial and equilateral fluoride atoms disordered also in a general position but resulting in distorted octahedral geometry. Connection of molecules in the crystal is mainly through C-H... F intermolecular interactions.
Packing in the crystal is such that the solvate molecules are sitting in the voids between the palladium complex molecules with the less disordered ions of PF6 being on the same axis as Pd atoms while the more disordered PF6 ion is positioned between the Pd complexes. In compound Pg 8, the conformations of the ligands are such that the pyridyl rings get positioned more above and below the coordination plane. Two pyridyl nitrogens, one on each side of the coordination plane are just over 3A from the Pd.
Table 1 : Crystal Data for [Pd(d2pyrpe)2][PF6]2
Study 1
The in vitro cytotoxic potency of 6 compounds in accordance with the invention and [Au(dppe)2]CI were investigated on various cells.
The following reagents were used:
■ Supplemented cell culture medium - Cell culture medium with 10% foetal calf serum (FCS). ■ Phosphate buffered saline (PBS).
■ DMSO (Sigma-Aldrich, Germany)
■ MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (Sigma Diagnostics Inc)
■ Phytohaemagglutinin (PHA) ■ Test compounds (6 and [Au(dppe)2]CI) - dissolved in DMSO (20 mM) and diluted in cell culture medium.
Various human and murine cancer cell lines (sources are indicated in parentheses) were grown as monolayer cultures at 37 °C in 5% CO2 in appropriate tissue culture medium (indicated in parentheses) supplemented with 10% v/v heat- inactivated serum (FCS) and 1% penicillin-streptomycin.
The following cancerous cell lines were used:
■ HeLa- human adenocarcinoma of the cervix (ATCC) (EMEM)
■ A2780- human ovarian cancer (EACC) (RPMI)
■ A2780-cis- human ovarian cancer-cisplatin resistant (EACC) (RPMI) ■ MCF-7- human breast cancer (ATCC) (DMEM)
■ CoLo 320 DM- human colon cancer (ATCC) (RPMI)
■ DU 145- human prostate cancer (ATCC) (RPMI)
■ Jurkat- human T-cell line (NRBM) (RPMI)
■ Novikoff- rat hepatocellular cancer (DKFZ) (RPMI) ■ B16- mouse melanoma (ATCC) (RPMI)
Normal cells included:
■ Human lymphocytes (resting and PHA stimulated)- fresh venous blood was obtained from healthy volunteers followed by isolation of lymphocytes. ■ Chicken embryo fibroblasts- cells were isolated from chicken embryos.
■ Porcine hepatocytes- obtained from the Bio-artificial liver project, Department of Internal Medicine, University of Pretoria.
Sample preparation
All the complexes were dissolved in DMSO to give a stock concentration of 20 mM (stored at -70°C). Immediately before the cell experiments, the stock solution was diluted in appropriate growth medium (containing 10% FCS) to give final DMSO concentrations not exceeding 0.5% and drug concentrations of 0.003-100 μM.
General procedure
The assays were performed using a metabolic assay based on the reactivity of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]. MTT is a pale
yellow substance that is metabolised to dark blue formazan crystals by metabolically active cells. The amount of formazan produced is directly proportional to the amount of cells over a wide range.
80 μl of medium (60 μl in the case of the lymphocytes earmarked to be stimulated) was dispensed into each well of a 96 well tissue culture plate (micro-titer plate). 100 μl of cell suspension (2 x 104 - 2 x 106 cells/ml/well depending on the cell type) was added and then allowed to incubate for 1 hour at 37QC in an atmosphere of 5% CO2 20 μl of the experimental drug (eight varying concentrations) was added in triplicate to the wells. However, control wells received 20 μl of growth medium instead of the experimental drug. Lymphocytes earmarked to be stimulated received 20 μl PHA 5 minutes after the addition of the drug.
After the incubation period (3 and 7 days for lymphocytes and cancerous cells respectively), 20 μl MTT (5 mg/ml) was added to each well and cultures were incubated for 4 hours. Cells were then centrifuged for 10 min at 2000 rpm (800 g)
(Beckman TJ 6 centrifuge) and the supernatant removed without disturbing the pellet.
The cells were washed with 150 μl PBS (per well) and centrifuged for 10 min at 2000 rpm (800 g) (Beckman TJ 6 centrifuge). The supernatant was removed and plates were left to dry in the dark. 100 μl DMSO was added to each well to solubilise the formazan crystals and the plates were shaken for 2-4 hours. Culture plates were read on a plate reader using a wavelength of 570 nm and a reference wavelength of 630 nm.
Statistical analysis
Percentage survival (percentage of the relevant untreated control systems) was calculated and this value was used to determine the IC5O value (IC5O = the concentration (μM) of the experimental compound inducing a 50% decrease in cell growth).
The IC5O value calculations were performed with the Graphpad™ program and are tabulated below in Table 2.
Table 2: IC50 values (μM) and S. E. M (±) of 7 compounds on various cancer cell lines as well as normal cells. The values are presented as a mean of three experiments carried out in triplicate.
In general the platinum complexes were less toxic than the palladium ones with Pg 1 being the least toxic compound followed by Pg 6 and Pg 5 { Table 2). Pg 8 was the most toxic of the palladium complexes followed by Pg 4a and Pg 3. With regard to all the novel complexes, prostate cancer (DU-145) was the most sensitive cell line (IC5O values of 0.253-9.380 μM) while ovarian cancer-cisplatin resistant cell line (A2780-cis) was the most resistant (IC5O values of 2.029-> 50 μM). Human ovarian cancer cell line- cisplatin sensitive (A2780) was sensitive to all the palladium complexes with IC50 values of 0.617 μM (Pg 3), 0.136 μM (Pg 4a) and 0.974 μM (Pg 8). Overall, Pg 8 was the most toxic (over the whole range of cells) of the novel compounds followed by Pg 4a which showed comparative activity against Jurkat and MCF-7 cell lines.
[Au(dppe)2]CI was more toxic than the novel compounds { Table 2). However, it exhibited non-selectivity as it was also toxic to both resting (IC5O = 0.903 μM) and stimulated lymphocytes (IC50 = 0.182 μM) while the experimental compounds were not toxic even at a concentration of 100 μM.
As indicated in Table 2, [Au(dppe)2]CI showed high potency, but non- selectivity. Pg 4a was the most selective with IC50 values of porcine hepatocytes and chicken embryo fibroblasts of 31 .08 and 2.379 μM respectively. Pg 8 gave comparable IC50 values among the cells with the lowest being 0.654 (Novikoff) and the highest being 1.755 (porcine hepatocytes).
Pg 8 was selected for further tests in an effort to elucidate its mechanism of action. It was selected due the fact that it showed greater toxicity to a wider range of cancer lines than the rest of the invention compounds. [Au(dppe)2]CI was included in these investigations as a standard. Jurkat cells were used for the remainder of the assays as they could be compared to lymphocytes.
Study 2
The aim of this assay was to evaluate the induction of apoptosis and/or necrosis by [Au(dppe)2]CI and Pg 8 on Jurkat cells with the Annexin V binding assay.
Untreated and treated cells were evaluated for apoptosis by flow cytometry. Camptothecin (1 μM), a topoisomerase I inhibitor that efficiently induces apoptosis in Jurkat cells was used as a positive control.
The following reagents were used:
■ RPMI and Foetal Calf Serum.
■ Phosphate buffered saline (PBS).
■ Binding buffer (238 mg Hepes, 876 mg NaCI, 37.3 mg KCI, 26.5 mg CaCI2, 9.5 mg MgCI2 in de-ionised water, at pH 7.4) ■ Annexin V- FITC ( BD Biosciences Pharmingen)
■ Propidium Iodide (Pl) (Sigma-Aldrich)
■ Camptothecin (1 μM) ( Sigma-Aldrich)
■ Pg 8 (0.71 1 and 1 .422 μM)
■ [Au(dppe)2]CI (0.131 and 0.262 μM)
The human Jurkat cell line was cultured in RPMI 1640 supplemented with 10% v/v heat-inactivated FCS and 1 % penicillin-streptomycin. Cells were maintained in a humidified atmosphere of 5% carbon dioxide at 37 °C.
Flow cytometric analysis of apoptosis
Cells (1 x 105 cells/ml) were treated with [Au(dppe)2]CI and Pg 8 for 18, 24 and 48 h in cell culture flasks. After the incubation period, cells were decanted from flasks and centrifuged for 5 min at 200 g. The cell pellet was washed with PBS (1 % FCS) and resuspended in 1 ml binding buffer. 100 μl of cell suspension was transferred to flow cytometer tubes. 5 μl of Annexin V-FITC and 10 μl propidium iodide were added to some tubes (unstained samples were also prepared). The cell suspensions were mixed gently and incubated for 15 min in the dark at room temperature (25 °C). 400 μl of binding buffer was then added to each tube and analysis was carried out within an hour with a flow cytometer (Beckman Coulter FC 500).
Statistical methods
All assays were performed at least three times and results are presented as ± S. E. M. The statistical evaluation of the results was performed by two way ANOVA followed by Bonferroni's Multiple Comparison Test. Significance was established at P<0.05.
Figure 3 shows graphs indicating the percentages of cells undergoing various stages of apoptosis. Figure 4 shows actual histograms of treated and untreated cells undergoing apoptosis (48 h). After incubation of Jurkat cells with the compounds for 18 and 24 h, no significant differences were noted between the untreated and the treated groups as between 85 and 90% of cells were viable. However, after exposure of the cells for 48 h, significant differences were observed. Untreated cells had an average of 85% of cells in a viable state and only 8% at the early apoptotic stage. [Au(dppe)2]CI (0.131 and 0.262 μM) induced apoptosis in 12% of the cells (9% in early apoptosis and 3% in the stage of late apoptosis) while 77% of the cells were still viable.
In contrast, Pg 8 (0.71 1 and 1 .422 μM) significantly induced apoptosis in 25% of the cells while 14% of cells had undergone necrosis. Only 50% of the cells were viable in this group. Unlike Pg 8 and [Au(dppe)2]CI, camptothecin (1 μM) induced apoptosis in Jurkat cells within a short time. After incubation for 6h, about 40% of the cells were in the late apoptotic stage. Viable cells were just over 50% while only 2% of the cells were necrotic. DNA topoisomerase I and Il inhibitors induce apoptosis in various cell lines and this is due to DNA-protein complex formation stabilised by DNA topoisomerase I inhibitors that ultimately signal the onset of apoptosis.
The two compounds behaved differently as observed from the histograms (Figure 4). [Au(dppe)2]CI treated group had more viable cells (77%) and very few in the necrotic stage (~4 %) while Pg 8 had a lower percentage of viable cells (50%) and most notably a much higher percentage of them in the necrotic stage (14%). This difference is significant as cytotoxicity assays showed that the former drug was more toxic (IC50 = 0.131 μM) while Pg 8 was at least 5 times less toxic (IC5O = 0.71 1 μM) to Jurkat cells. The mode of cell killing differs as [Au(dppe)2]CI mainly induced apoptosis while Pg 8 seemed to induce both apoptosis and necrosis. While the former compound was toxic
to lymphocytes (IC50 = 0.903 μM), Pg 8 was not cytotoxic even at 100 μM. This selectivity for cancer cells by the latter compound may be due to this difference in induction of cell death (necrosis vs. apoptosis). However, it is not clear which factors play a role in triggering an apoptotic or necrotic pathway in the different cells (lymphocytes vs. Jurkat cells).
Study 3
Study 2 has shown that Pg 8 and [Au(dppe)2]CI caused Jurkat cells to undergo apoptosis after exposure for 48 h. The aim of this study was to determine if cell death was as a result of cell cycle arrest by these compounds. Cell cycle analysis was performed using flow cytometric evaluation of DNA content.
The following reagents were used: ■ RPMI and foetal calf serum
■ RNase ( Sigma-Aldrich)
■ Propidium Iodide (Pl) ( Sigma-Aldrich)
■ Phosphate buffered saline (PBS)
■ Ethanol (100%) (Sigma-Aldrich) ■ Pg 8 (0.71 1 and 1 .422 μM)
■ [Au(dppe)2]CI (0.131 and 0.262 μM)
The human Jurkat cell line was cultured in RPMI 1640 supplemented with 10% v/v heat-inactivated FCS and 1 % penicillin-streptomycin. Cells were incubated with the experimental compounds for 18, 24 and 48 hours at 37 °C and 5% carbon dioxide.
Flow cytometric analysis of cell cycle progression
Cells (1 x 105 cells/ml) were treated with [Au(dppe)2]CI and Pg 8 for 18, 24 and 48h in cell culture flasks. After the incubation period, they were decanted from flasks and centrifuged for 5 min at 200 g. The cell pellet was re-suspended in 500 μl PBS and chilled on ice. The cold cell suspension was then added rapidly to flow cytometer tubes containing 500 μl of ice cold ethanol. Mixing was carried out by forcing
air bubbles through the suspension and then kept on ice for 15 minutes. The cells were then centrifuged for 3 minutes at 300 g followed by suspension of the cell pellet in 125 μl of RNAse (2mg/ml 1 .12% w/v sodium citrate). After incubation for 15 minutes at 37 °C in a water bath, 125 μl of Pl was added to each tube and mixed well. Samples were allowed to stand for 30 minutes at room temperature before analysis by flow cytometry (Beckman Coulter FC 500). DNA histograms were collected and estimation of the percentages of cells in Gi , S and G2/M was performed with a computer software program (Multicycle, Phoenix Flow systems, San Diego, CA).
Statistical methods
All assays were performed at least five times and all data are presented as ± S. E. M. Differences in the cell cycle profiles (G0/G1, S and G2/M phases) of untreated and treated cells were also compared by ANOVA (2-way) followed by Bonferroni's Multiple Comparison Test. Significance was established at P<0.05.
Representative histograms and graphs showing changes in the cell cycle profiles (G0/Gi, S and G2/M phases) after 18, 24 and 48 hours with or without exposure to the experimental compounds are shown in Figures 5 to 9.
At 24 h, there was a decrease in the number of cells in Gi phase (from 63 to 58%), which was complimented by a slight increase in the number of cells in the S- phase (from 29 to 38 %). At 48 h, there was a decrease in the S-phase (from 38 % to 35 %) and a marked increase in the G2 phase (from 4 to 1 1 %). The observed changes in the cell cycle progression of untreated cells were used to determine if any changes had occurred in the treated samples (Figures 6-9).
Cells exposed to 0.71 1 μM of Pg 8 for 18 and 24 h did not exhibit any differences in cell cycle progression (Figure 6). After 48 h, the number of cells in Gi was significantly reduced (from 61 to 47%) with the subsequent accumulation of cells in
S-phase (from 36 to 57%). Due to this blockade of the S-phase, G2 phase contained virtually no cells (1 %).
Cells exposed to 1.422 μM of Pg 8 (Figure 7) showed the same behaviour as the ones exposed to half the concentration. After 48 h, the number of cells in Gi was significantly reduced (from 62 to 47 %) with the subsequent accumulation of cells in S- phase (from 36 to 58%). There were no cells in the G2 phase.
After exposure of Jurkat cells to [Au(dppe)2]CI (0.131 μM) for 18 h and 24 h, no significant changes to progression of cell cycle were observed (Figure 8). However, significant changes were observed after 48h. The number of cells in Gi decreased from
68 to 61 % while there was an increase in S-phase (from 28 to 34%). The number of cells in G2 phase increased insignificantly (from 4 to 5%).
Cells exposed to 0.262 μM of [Au(dppe)2]CI showed the same pattern as those exposed to half the concentration (Figure 9). At 48 h, the number of cells in Gi decreased from 69 to 64 % while S-phase increased from 28 to 34%. G2 phase showed an insignificant decrease (from 4 to 3%).
The DNA histogram yields the relative number of cells in G1ZG0, S, and G2/M phases of the cell cycle. Although some information about cell cycle progression can be deduced by following changes in the cell cycle phases with time, it gives static information. For example, although it is possible to estimate the percentage of cells in S phase, the measurement does not directly tell whether those cells are still moving through the S phase. A very distinct connection has been forged between the cell cycle clock apparatus and apoptosis. The paclitaxel-induced apoptosis of human breast cancer cells has been found to depend upon the induction of the cdc2 kinase at the G2/M phase transition of the cell cycle.
Comparison of untreated and treated cells at different time intervals showed significant changes (Figure 10). At 18 h, cells treated with Pg 8 (0.71 1 and 1 .422 μM) showed an increase of cells (P<0.05) in the G0/Gi phase but there was no complimentary decrease in the number of cells in either the S or G2 phase. After 24 h, only cells treated with [Au(dppe)2]CI (0.130 and 0.262 μM) showed any changes in cell cycle progression. There was a significant increase (P<0.01 ) in the number of cells in the G0/G1 phase with a concomitant decrease in the number of cells in the S-phase. After 48 h, the treated cells showed significant differences in the cell cycle sequence.
Cells treated with [Au(dppe)2]CI (0.262 μM) had significantly larger number (P<0.05) of cells in G0/Gi phase than the untreated cells. However, this difference was not as large as that observed at 24 h. It is probable that [Au(dppe)2]CI induced apoptosis was not necessarily as a result of cell cycle arrest.
In contrast, cell cycle progression at 48 h was greatly perturbed by Pg 8. The number of cells in Gi phase was reduced by 15% while those in the S-phase increased by 22% at both concentrations (P<0.01 ). There were no cells detected in the G2 phase due to this blockade in the S-phase. Taken together, these results indicate that Pg 8 inhibited cellular proliferation of Jurkat cells via an S-phase arrest of the cell cycle following exposure for 48 h.
Study 4
This study was carried out in order to establish the safe dosage or maximum tolerated dose (MTD) of Pg 8 in mice.
Ethical approval by the AUCC (Animal Use and Care Committee) was obtained (Protocol No. H1706). The study was conducted at the University of Pretoria Biomedical Research Centre (UPBRC) from 24-29 August 2006 and 22-27 September 2006.
Inbred female Balb/C mice of 6-8 weeks were used and housed in standard mouse cages in rooms with controlled environmental conditions. The animals were fed normal pellets (EPOL (trade name)) and water ad libitum.
The study was carried out in two phases with 4 groups of 6 mice each being used per phase (total of 48 mice). The MTD of [Au(dppe)2]CI was previously shown to be 3.0 μmol/kg/day for 5 days and hence this concentration was used as a guideline. The weight of the mice was determined to adapt the dosages according to their body weight. The experimental compound Pg 8 and [Au(dppe)2]CI (standard) were dissolved in analytical quality ethanol, with subsequent addition of water to make up a final dose volume of 0.5 ml and a concentration of 5% ethanol. The dosages were prepared immediately prior to each ip. administration. [Au(dppe)2]CI was soluble in ethanol, while
Pg 8 (15 μmol/kg) was sparingly soluble. Solubility was achieved by sonic bath solvation for 15 minutes. Both compounds precipitated out slightly and were mixed prior to injection.
Tables 3 and 4 below summarise the number of animals and dosages used in both phase 1 and phase 2.
The total duration of the study was 10 days and each group of mice was injected ip. each day for 5 days. For phase 1 , the ethanol-water solution and the first and second dosages of 3 μmol/kg and 6 μmol/kg were administered each day from day 1 to 5. Phase 2 followed whereby the ethanol-water solution and the third and fourth dosages of 12 μmol/kg and 15 μmol/kg were administered each day from day 1 to 5. At the end of the study, the mice were weighed followed by anaesthetisation via isoflurane inhalation. While they were at the surgical plane of anaesthesia, maximum blood was drawn via cardiac puncture. The animals were then further exposed to isoflurane until death occurred. Mice in phase 2 were dissected and major organs (liver, heart and kidneys) were weighed.
Body weights were recorded immediately prior to dosing (on day 1 ) so that an objective monitoring of weight could be done, indicating food intake, which is a good measure for animal well-being. The animals were also monitored for pain and stress (behavioural changes) immediately after the injection.
A whole blood profile was done on all the blood samples by the Department of Clinical Pathology at the Faculty of Veterinary Science (University of Pretoria). Standard liver enzymes (Aspartate aminotransferase (AST) and Gamma glutamyltransferase (GGT)) were also analysed, as well as levels of serum creatinine. Toxicity was to be determined if adverse effects were observed on the experimental animals or with elevated liver enzymes.
Statistical analysis on levels of AST, GGT and creatinine was done on
Graphpad™ by One Way Analysis of Variance (ANOVA) followed by Bonferroni's Multiple Comparison Test. Significance was indicated if P < 0.05.
The acute toxicities of [Au(dppe)2]CI and Pg 8 were examined in mice after ip. administration for 5 days. On the second day of the study (in both phases), mice injected with the former compound made squeaking sounds upon injection. This sign of discomfort was not observed for the remainder of the study. The most significant difference between the groups treated with [Au(dppe)2]CI and the rest of the groups was that the former batch had a greatly reduced weight gain. They lost an average of 7.6%
of their total body weight in phase 1 and 12.4% in phase 2. The groups treated with Pg 8 showed similar weight gain to the control group in phase 1 (average of 2.9%) but a reduced weight gain in phase 2 (average of 1 % vs. 4.7 % in control group). Figures 1 1 and 12 show the weight changes in phase 1 and 2 respectively.
Immediately after completion of phase 2, the major organs were surgically removed and weighed. The results are tabulated in Table 5.
No significant gross pathologic differences were observed between the control and treated groups. The average heart and kidney weights did not differ significantly among all the groups but the mean liver weights of the mice exposed to [Au(dppe)2]CI were greater than the rest. This could be as a result of highly reduced body weight gain. No significant difference in full blood counts was observed as haematological parameters between the untreated and treated groups did not vary.
Analysis of liver enzyme AST, showed that there were no significant differences in their levels in all the groups (untreated and treated) in Phase 1 (Figure 13). However, in Phase 2, the mice treated with [Au(dppe)2]CI (6 μmol/kg) had
significantly elevated levels of AST (P<0.001 ). These levels of AST were significantly higher than those found in the untreated and Pg 8 (12 and 15 μmol/kg) treated mice (Figure 14).
GGT levels shown in Figure 15 were also slightly elevated (P <0.05) in the group treated with [Au(dppe)2]CI (3 μmol/kg) when compared to the untreated mice. However, the levels did not differ significantly with the mice treated with Pg 8 (12 and 15 μmol/kg). In Phase 2 of the study, GGT levels did not show significant differences in all the groups (untreated and treated). Notably, the mice treated with 12 μmol/kg of Pg 8 exhibited higher levels of GGT than the highest dose (15 μmol/kg) (Figure 16). However, this difference was not significant.
Creatinine levels (Figure 17 and 18) in all the groups did not vary significantly. This is an indication of lack of toxicity to the kidneys.
No significant differences in full blood counts were observed as haematological parameters between the untreated and treated groups did not vary.
In conclusion, [Au(dppe)2]CI showed greater in vitro activity against cancer cells than Pg 8. It was also very toxic to the normal cells such as lymphocytes, chicken embryo fibroblasts and hepatocytes. This lack of selectivity is exhibited in vivo as the acute exposure to mice caused reduced body weight. Measurement of biochemical parameters revealed that AST levels were greatly elevated which may imply damage to organs. As an intracellular enzyme, AST is released into the blood in proportion to the number of damaged cells. While the former drug may show potency against cancer cell lines, its lack of selectivity is dose-limiting. As mentioned earlier, it was also active in tumour implanted mice.
Pg 8 was more tolerable although the group treated with the highest dose (15 μmol/kg) showed slightly reduced weight gain as compared to the rest (3, 6 and 12 μmol/kg). The desired outcome is that the compound shows in vivo anti-tumour activity especially in distal tumours. This would be determined by good bio-availability which is influenced by factors such as stability against metabolic, pathways, adsorption, plasma level concentrations and excretion rates.
Study 5
Uptake of [103Pd(d2pyrpe)2][PF6]2 and [198Au(dppe)2]CI by Jurkat cells
Reagents
■ RPMI and foetal calf serum
■ Phosphate buffered saline (PBS)
■ 103Pd labelled [Pd(d2pyrpe)2][PF6]2 (Pg 8)- 5 and 10 μM in DMSO ■ 198Au labelled [Au(dppe)2]CI- 5 and 10 μM in DMSO
Cell lines and culture
Human T-cell lines (Jurkat) were cultured in RPMI 1640 supplemented with 10% v/v heat-inactivated FCS and 1 % penicillin-streptomycin. The cell culture was maintained at 37 0C and 5% CO2.
Experimental procedure
200 μl of radiolabeled Pg 8 and [Au(dppe)2]CI (both at a concentration of 5 and 10 μM) were added to test tubes containing a suspension (1 ,800 μl) of Jurkat cells (5 x 106 cells/ml). The mixture was incubated while mixing at 37 °C (+ 5% CO2) for 1 hr. After incubation, the cells were centrifuged at 800 g (2000 rpm TJ 6) for 10 min. The supernatant was poured into new, clean, marked 5 ml test tubes (kept separately). The pellet was resuspended in PBS (3 ml) and centrifuged as before. The PBS was poured into new, clean, marked 5 ml test tubes and keep separately. The tubes were counted separately using 1261 multigamma manual gamma counter (LKB Wallac).
Statistical methods
Cells from eight different cell culture flasks were used for these assays. The activity that was obtained from the experiments was determined from counts per minute (CPM). Hence this represented the amount of compound distributed either in the supernactant or cell. Statistics was carried out on Graphpad™ and One Way Analysis
of Variance (ANOVA) followed by Bonferroni's Multiple Comparison Test to determine significance between the two experimental compounds in the cells and/or supernactant. P< 0.001 was considered significant.
In general, there was a significant difference (P< 0.001 ) between the amounts of compound taken up into the cells when compared to the amount left in the supernactant for both complexes (Figure 19). After incubation for 1 h, [198Au(dppe)2]CI (5 and 10 μM) was taken up into the cells at significantly larger amounts (P< 0.001 ) than [103Pd(d2pyrpe)2][PF6]2 (5 and 10 μM). This large difference in uptake may be as a consequence of lipophilicity. The former compound was found to be more lipophilic (log P= 0.362) than the former (log P= -0.093) and hence able to pass through the lipid layers of cells more rapidly.
In both compounds, the higher concentration (10 μM) was found to accumulate in larger amounts (P< 0.001 ) than the lower concentration (5 μM). Uptake studies of [14C][Au(dppe)2]CI by isolated rat hepatocytes showed that rapid maximal uptake took place within 30 min. The amount of radiolabeled drug associated with hepatocytes was also concentration-dependent. The authors proposed that the mechanism by which [Au(dppe)2]CI gained access to the intracellular compartments was most likely linked to its lipid solubility. In other experiments, NMR studies showed that nearly half of the [Au(dppe)2]CI added to plasma was transferred into cells.
Experiments on red cell ghosts confirmed that the complex can bind intact in the membrane.
Study 6
Biodistribution of [103Pd(d2pyrpe)2][PF6]2 and [198Au(dppe)2]CI in rats
This study was carried out by NECSA at the University of Pretoria Biomedical Research Centre (UPBRC). Animal experimentation was done according to the National
Code for the Handling and Use of Animals in Research, Education, Diagnosis and
Testing of Drugs and Related Substances in South Africa. Ethical approval by the
AUCC (Animal Use and Care Committee) was obtained (Protocol No. H1206) and the
study was done according to the rules and regulations laid down by the International Controlling Body for Radioisotope Studies.
Adult male Sprague Dawley rats were used to follow the biodistribution on a gamma camera. Animals were screened from time to time to see when the biodistribution reaches a stable state.
Six rats per compound were obtained from the Onderstepoort facility in South Africa. The animals were kept in separate cages. The animals were fed a balanced diet and water was available ad libitum.
Six rats were injected each with a extremely low, non-toxic dosage of radio- labelled compound (198Au labelled [Au(dppe)2]CI, 103Pd labelled [Pd(d2pyrpe)2][PF6]2). The rats were terminated at the end of each day by an lsoflurane overdose, and the organs counted in a well type gamma counter.
The experimental procedure used was as follows:
140μl dimethylsulphoxide, 800μl EtOH and 3200μl H2O were added to 75 mg Pg 8. The filtered 4000μl fraction had an activity of 3μCi (9:00; 30 November
2006). An injection volume of 450μl and an activity of 0.3μCi was used (7.5X10"4 μCi/μl).
1200μl EtOH and 7200μl H2O was added to 1 1 .43mg [Au(dppe)2]CI. A 3000μl fraction was filtered (Millex GP 0.22 μm). An injection volume of
500μl and an activity of 25μCi was used (5.0X10"2μCi/μl).
On the day of the experiment, the animals were anaesthetised by an intraperitoneal (ip.) injection of a 6 % sodium pentobarbitone solution at a dose of 1 ml/kg. A 24 G jelco was inserted into the tail vein of the animals to administer the radio- labelled compounds. Two animals per group were scanned in parallel with an Elscint Gamma Camera at the Diagnostic Imaging unit at Onderstepoort in order to obtain the radionuclide imaging. Two minute static studies were performed every half an hour up
to 6 hours, lsoflurane was used to immobilize the animals for the 2 minute static studies.
The animals were sacrificed using an lsoflurane overdose after a 6 hour period. The organs were separated and counted in a well type counter at NECSA. From the organ counts as well as the reference activity in a syringe the %ID/g (Injected Dose/gram) was calculated.
The biodistribution (Figure 20) showed predominantly high reticulo- endothelial uptake for all compounds. The largest concentration of [Au(dppe)2]CI was found in the lungs followed by the spleen. The highest concentration of Pg 8 was found in the spleen followed by the liver. Hydrophilic drugs are expected to have a limited biodistribution compared to lipophilic drugs. This might imply a more selective tumour uptake.
Claims
1. A phosphine complex of the general formula (I)
in which M is Pt or Pd;
R1 and R2 are independently Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl; the two Y substituents are independently CH2CH2 or CH=CH; and X is hexafluorophosphate, halogen or pseudo-halogen.
2. The phosphine complex as claimed in claim 1 , which is selected from the group consisting of
3. The phosphine complex as claimed in claim 2, which is selected from the group consisting of
5. The phosphine complex as claimed in claim 2, which is selected from the group consisting of
6. The phosphine complex as claimed in claim 2, which is
7. A substance or composition for use in the treatment of cancer, the substance or composition including a phosphine complex as claimed in any of claims 1 to 6 inclusive.
8. A pharmaceutical composition which includes a phosphine complex as claimed in any of claims 1 to 6 inclusive, or a pharmaceutically acceptable salt thereof.
9. The use of a phosphine complex as claimed in any of claims 1 to 6 inclusive in the manufacture of a medicament for use in the treatment of cancer.
10. A process for the preparation of a phosphine complex of the general formula (I)
in which M is Pt or Pd;
R1 and R2 are independently Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl; the two Y constituents are independently CH2CH2 or CH=CH; and
X is hexafluorophosphate, halogen or pseudo-halogen, the process including
reacting
in which R1 and R2 are independently Ph, 2-pyridyl, 3-pyridyl or 4-pyridyl, and Y is
CH2CH2 Or CH=CH, with M 1 2 M2 HaI4 in which M1 is an alkali metal, M2 is Pd or Pt and Hal is Cl or Br to produce an intermediate compound of formula (I) in which X" is Cl" or Br".
1 1 . The process as claimed in claim 10, which includes reacting the intermediate compound of formula (I) with a hexafluorophosphate salt to produce the compound of formula (I) in which X" is PF6 ".
12. The process as claimed in claim 10 or claim 1 1 , in which M1 is Na, M2 is
Pd and Hal is Cl so that M1 2 M2 HaI4 is Na2PdCI4.
13. The process as claimed in any of claims 10 to 12 inclusive, in which R1 and R2 are both 2-pyridyl.
14. The process as claimed in any of claims 10 to 13 inclusive, which includes rreeaadcting M 1 2 M2 HaI4 in which M2 is Pd with
in which Y is CH2CH2
15. The process as claimed in claim 1 1 , in which the hexafluorophosphate salt is NH4PF6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA2008/01749 | 2008-02-22 | ||
ZA200801749 | 2008-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009104167A1 true WO2009104167A1 (en) | 2009-08-27 |
Family
ID=40566529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2009/050712 WO2009104167A1 (en) | 2008-02-22 | 2009-02-20 | A substance or composition for the treatment of cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009104167A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210371441A1 (en) * | 2020-05-22 | 2021-12-02 | City University | Platinum complex, its preparation and therapeutic use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0227127A2 (en) * | 1985-10-25 | 1987-07-01 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO | Pharmaceutically active phosphino-hydrocarbon-group VIII-metal complexes, antitumor compositions containing these complexes, and a process for preparing said compounds or antitumor compositions |
EP1876182A1 (en) * | 2005-04-18 | 2008-01-09 | Nippon Chemical Industrial Co., Ltd. | Phosphine transition metal complex, process for producing the same and anticancer drug containing the same |
-
2009
- 2009-02-20 WO PCT/IB2009/050712 patent/WO2009104167A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0227127A2 (en) * | 1985-10-25 | 1987-07-01 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO | Pharmaceutically active phosphino-hydrocarbon-group VIII-metal complexes, antitumor compositions containing these complexes, and a process for preparing said compounds or antitumor compositions |
EP1876182A1 (en) * | 2005-04-18 | 2008-01-09 | Nippon Chemical Industrial Co., Ltd. | Phosphine transition metal complex, process for producing the same and anticancer drug containing the same |
Non-Patent Citations (4)
Title |
---|
JONES, NATHAN D. ET AL: "Coordination Chemistry of the 2-Pyridyldiphosphine Ligands, (py)2Pcyclo-(CH(CH2)3CH)P(py)2 and (py)2P(CH2)2P(py)2 (py = 2-Pyridyl), with Platinum(II) and Ruthenium(II). Ruthenium-Catalyzed Hydrogenation of Imines", INORGANIC CHEMISTRY , 38(18), 3956-3966 CODEN: INOCAJ; ISSN: 0020-1669, 1999, XP002522832 * |
NOH ET AL: "Synthesis of platinum(II) complexes containing diphosphines and evaluation of antitumor activity", CA HOST- CA, 1990, XP002522835 * |
SCHURIG ET AL: "Antitumor activity of bis[bis(diphenylphosphino)alkane and alkene] group VIII metal complexes", CA HOST- CA, 1989, XP002522836 * |
SCHURIG JOHN E ET AL: "Antitumor activity of bis[bis(diphenylphosphino)alkane and alkene] group VIII metal complexes", RUTHENIUM AND OTHER NON-PLATINUM METAL COMPLEXES IN CANCER CHEMOTHERAPY, SPRINGER, BERLIN, vol. 10, 1 January 1989 (1989-01-01), pages 205 - 216, XP008105055, ISBN: 978-3-540-51146-5 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210371441A1 (en) * | 2020-05-22 | 2021-12-02 | City University | Platinum complex, its preparation and therapeutic use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fitzharris et al. | VP16-213 as a single agent in advanced testicular tumors | |
CN103781760A (en) | Metal salen complex compound, local anesthetic, and anti-malignant tumor agent | |
JPH0296523A (en) | Platinum chemical remedy product | |
JPH05503077A (en) | Iludin analogs as antitumor agents | |
CN101475596B (en) | Platinum complexes of quercetin and derivatives thereof, as well as preparation and use thereof | |
JP5553275B2 (en) | Metal complex and anticancer agent containing this as active ingredient | |
CN104434939A (en) | Antitumor medicament composition of panax notoginseng saponins R7 and oridonin with capabilities of reducing toxicity and enhancing efficacy and application of antitumor medicament composition | |
WO2009104167A1 (en) | A substance or composition for the treatment of cancer | |
EP0686038A1 (en) | Combination cisplatin/tamoxifen therapy for human cancers | |
Pal et al. | Anticancer potential of Pd and Pt metallo-macrocycles of phosphines and 4, 4΄-dipyridyldiselenide | |
Sancho et al. | The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study | |
Yang et al. | Dicycloplatin, a platinum-based supramolecule with 4 hydrogen bonds, is a promising chemotherapy drug | |
JP7065866B2 (en) | Use of non-transition metal-coordinated dipyridoxyl compounds to prevent and treat chemotherapy-induced PSN | |
EP3755383B1 (en) | Tricarbonyl complexes of transition metals with benzo-heterocyclic derivatives of the cyclopentadienyl anion | |
KR101394878B1 (en) | Novel hexanuclear Arene-Ruthenium nano prismatic cage compound, preparation method thereof and pharmaceutical composition for preventing and treating cancer as active ingredient | |
DE69831158T2 (en) | HYDROXYMETHYL PHOSPHINE DERIVATIVES FOR USE AS DIAGNOSTIC AND THERAPEUTIC MEDICAMENTS AND THEIR METHODS | |
FI91753C (en) | Process for the preparation of a therapeutically useful complex containing tellurium | |
EP4311830A1 (en) | Cisplatin analogue with potent anti-cancer effects and synthesis thereof | |
Los et al. | Combination treatment of cis-and carboplatin in cancers restricted to the peritoneal cavity in the rat | |
US10675300B2 (en) | Group 3 metal compounds and use thereof in the treatment of solid tumors | |
CN106038551A (en) | Application of composition of Schiglautone A derivatives in preparation of low-erythrocyte anemia preventive drugs | |
US20210395280A1 (en) | Targeting Redox-Active Pyridinium Cations to Mitochondria to Inhibit Proliferation of Drug-Resistant Cancer Cells | |
WO2024023197A1 (en) | Cisplatin analogue with potent anti-cancer and cancer stem cell-targeting effects and synthesis thereof | |
Engel et al. | Estrophilic cisplatin derivatives | |
BR102014022630A2 (en) | composition of a copper (ii) complex and binder - [bis (pyridin-2-ylmethyl) amino] -3-chloropropan-2-ol and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09712299 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09712299 Country of ref document: EP Kind code of ref document: A1 |